Dr. Christopher E. Barbieri, MD, PhD

Dr. Barbieri practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Barbieri's NPI, 1225296593, was assigned on May 23, 2008. Dr. Barbieri graduated from Vanderbilt University School Of Medicine in 2007. Dr. Barbieri holds New York license 251738.

Dr. Barbieri's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Barbieri's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Barbieri to 2 more clinical labs and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barbieri practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Barbieri's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Barbieri is board certified in urology by the American Board of Urology. Dr. Barbieri is licensed in New York.

Dmand AI lists enlarged prostate, kidney removal surgery, prostate cancer, prostate surgery and urinary endoscopy among the conditions Dr. Barbieri treats.

CMS data shows 1,157 Medicare services from Dr. Barbieri across 14 procedure codes in 2024, for 263 Medicare patients. Medicare paid $90,388 for them.

CMS counts 263 Medicare patients who saw Dr. Barbieri in 2024. The largest group is 65 to 74, with 139 patients. 75% of them have high cholesterol, and 71% have cancer. 7% are also on Medicaid. Their average risk score is 1.14, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Barbieri's median patient age at 67, with 5% women.

In 2024, Dr. Barbieri wrote 71 Medicare Part D claims for 24 patients. 99% of them were for generic drugs. CMS names the drug for 49 of them, across 1 drug with 11 or more claims each, at $631 in total drug cost. In 2023, CMS named 19 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Barbieri for performance year 2024, reported through an alternative payment model (APM). Dr. Barbieri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Barbieri as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 92 papers to Dr. Barbieri, published from 2007 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Prostate and Gene Expression Regulation, Neoplastic. Dr. Barbieri has published most often in J Urol. Dr. Barbieri's most frequent co-authors are Brian Dale Robinson, MD, Douglas Scott Scherr, MD and Jim C. Hu, MD, MPH.

CMS Open Payments shows 28 general payments to Dr. Barbieri from 9 drug and device companies from 2016 to 2025. Grants make up the largest share, 80% of the total. Genentech, Inc. paid the most, $18,785.

Dmand AI lists 4 awards for Dr. Barbieri, most recently MetLife Clinical Investigator Award in 2016.

Dr. Barbieri graduated from Vanderbilt University School Of Medicine in 2007. Dr. Barbieri is a member of AOA, AACR and AUA.

Dr. Barbieri is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.